Certara Inc. (NASDAQ:CERT), a key player in the Medical - Biomedical and Genetics industry, offers software and services designed to accelerate drug development. On February 26, 2026, Leerink Partners reiterated its "Outperform" rating for Certara, with the stock priced at around $6.39. This recommendation, as reported by StreetInsider, suggests investors hold the stock.
The company's recent earnings report revealed a quarterly earnings per share (EPS) of $0.09, which fell short of the Zacks Consensus Estimate of $0.11, marking a 20.57% negative surprise. This is a decrease from the EPS of $0.15 reported in the same quarter last year. Despite this, Certara has managed to exceed consensus EPS estimates twice in the past four quarters.
In terms of revenue, Certara announced $103.65 million for the quarter ending December 2025, slightly beating the Zacks Consensus Estimate by 0.41%. This represents an increase from the $100.36 million reported in the same period the previous year. The company has surpassed consensus revenue estimates three times in the last four quarters.
Currently, Certara's stock is trading at $6.61, indicating a slight increase of 0.23% or $0.015. The stock has seen a low of $6.04 and a high of $6.66 today. Over the past year, the stock has reached a high of $15.38 and a low of $6.04. Certara boasts a market capitalization of approximately $1.05 billion, with a trading volume of 2,780,555 shares.
